Zynex (NASDAQ:ZYXI) Stock, Quote.Headers.trade-ideas

Zynex

Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.

xr:d:DAFqNaIkdw0:2,j:153520640059868796,t:23073113

News

Intraday Update

Markets

Movers

Trading Ideas

AEYE

ATUS

AVGR

AVTR

BIIB

BJRI

CHTR

CMAX

COLB

COUR

CREV

DECK

DOUG

DXCM

EVRI

FWRD

GROM

KARO

KITT

LBRDA

NMHI

Next Technology Holding Inc. - Ordinary Shares

NXTT

OPTT

PAPL

POAI

PSIG

SAIA

SDST

SGMO

SLNA

TANH

TARS

TNDM

TWOU

UCTT

VSAT

WINT

WRLD

ZYXI

Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Image30

Pre-Market Outlook

INDV

MGNX

DexCom, Zynex, Olin And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

CONN

XCUR

ZPTA

Why Ultra Clean Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket

Zynex Inc

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4323650-1&amp;h=1847303498&amp;u=http%3A%2F%2Fwww.zynex.com%2F&amp;a=Zynex%2C+Inc">Zynex, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) ("Zynex", "ZMS", "we" or the "Company"),&nbsp;an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced highlights from a recent study comparing its NiCO&#x2122; laser pulse oximeter to conventional LED pulse oximeters for the effects of skin pigmentation on SpO2 measurements conducted by the University of California, San Francisco (UCSF) Hypoxia Lab.
Zynex's NiCO pulse oximeter utilizes highly precise laser technology to measure blood oxygenation levels directly, as opposed to current pulse oximeter products, which only estimate oxygenation levels using an LED-based technology. LED pulse oximeters have been shown to mismeasure oxygen levels in several populations, most prominently in individuals with darker skin pigmentation.
A poster presentation for the study was recently accepted and presented at the ANESTHESIOLOGY 2024 Event hosted by the American Society of Anesthesiologists that took place October 18 - 22 in Philadelphia. The presentation titled, "Laser-Based Pulse Oximetry Eliminates Effects of Skin Pigmentation on SpO2 Measurements," included results from a study conducted under the supervision of Dr. Philip Bickler at the UCSF Hypoxia Lab.
Nine darkly pigmented and nine lightly pigmented participants were recruited for this controlled desaturation study. Four NiCO pulse oximeters and two different commercially available LED-based pulse oximeters were used on each participant. Conclusions from the study showed the NiCO pulse oximeter did not demonstrate a bias for dark pigmented participants compared to lightly pigmented participants. By comparison, conventional LED-based pulse oximeters in the present study read falsely higher on darkly pigmented participants, specifically at lower oxygen saturation levels.

Biotech

General

Zynex Announces Highlights From A Recent Study Comparing Its NiCo Laser Pulse Oximeter To Conventional LED Pulse Oximeters For The Effects Of Skin Pigmentation On SpO2 Measurements Conducted By The University Of California, San Francisco Hypoxia Lab

HC Wainwright &amp; Co. analyst Yi Chen reiterates Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) with a Buy and maintains $17 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Zynex, Maintains $17 Price Target

Zynex Completes Clinical Trial For NiCO Laser Pulse Oximeter, Achieving Key FDA Milestone Ahead Of 510(k) Clearance Submission For Clinical Use

HC Wainwright &amp; Co. analyst Yi Chen maintains Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) with a Buy and raises the price target from $16 to $17.

HC Wainwright & Co. Maintains Buy on Zynex, Raises Price Target to $17

Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) .

Guidance

Zynex FY 2024 Net revenue estimated to be at least $200M (Est. $200.520M). Diluted EPS is expected to be at least $0.20 (Est. $0.20)

Zynex Q4 2024 revenue is estimated to be at least $53.6M (Est. $53.287M). Diluted EPS is estimated to be at least $0.09 (Est. $0.10).

Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.06 by 16.67 percent. The company reported quarterly sales of $49.966 million which missed the analyst consensus estimate of $50.827 million by 1.69 percent. This is a 0.10 percent increase over sales of $49.915 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Zynex Q3 2024 GAAP EPS $0.07 Beats $0.06 Estimate, Sales $49.966M Miss $50.827M Estimate

Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) is gearing up to announce its quarterly earnings on Thursday, 2024-10-24. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Zynex will report an earnings per share (EPS) of $0.06.
The announcement from Zynex is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Overview of Past Earnings</h3>
The company's EPS missed by $0.04 in the last quarter, leading to a 12.37% drop in the share price on the following day.
Here's a look at Zynex's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.08</td>
<td>0.03</td>
<td>0.17</td>
<td>0.09</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.04</td>
<td>0</td>
<td>0.04</td>
<td>0.10</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-12.0%</td>
<td>7.000000000000001%</td>
<td>-9.0%</td>
<td>17.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1729713700_0.png" alt="eps graph" />
<h3>Performance of Zynex Shares</h3>
Shares of Zynex were trading at $8.53 as of October 22. Over the last 52-week period, shares are up 16.5%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Take on Zynex</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Zynex.
The consensus rating for Zynex is Buy, derived from 4 analyst ratings. An average one-year price target of $13.75 implies a potential 61.2% upside.
<h3>Analyzing Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Sight Sciences, Pulmonx and AngioDynamics, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>The prevailing sentiment among analysts is an Buy trajectory for Sight Sciences, with an average 1-year price target of $10.0, implying a potential 17.23% upside.</li>
<li>For Pulmonx, analysts project an Buy trajectory, with an average 1-year price target of $12.67, indicating a potential 48.53% upside.</li>
<li>For AngioDynamics, analysts project an Buy trajectory, with an average 1-year price target of $13.33, indicating a potential 56.27% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Sight Sciences, Pulmonx and AngioDynamics, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zynex</td>
<td>Buy</td>
<td>10.97%</td>
<td>$39.91M</td>
<td>3.69%</td>
</tr>
<tr>
<td>Sight Sciences</td>
<td>Buy</td>
<td>-8.95%</td>
<td>$18.34M</td>
<td>-11.69%</td>
</tr>
<tr>
<td>Pulmonx</td>
<td>Buy</td>
<td>20.87%</td>
<td>$15.31M</td>
<td>-14.48%</td>
</tr>
<tr>
<td>AngioDynamics</td>
<td>Buy</td>
<td>-14.22%</td>
<td>$36.72M</td>
<td>-6.36%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Zynex ranks first in revenue growth among its peers. It has the highest gross profit margin. Zynex has the highest return on equity.
<h3>All You Need to Know About Zynex</h3>
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.
<h3>Zynex's Economic Impact: An Analysis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Zynex's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 10.97%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 2.44%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Zynex's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.69%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Zynex's ROA excels beyond industry benchmarks, reaching 0.98%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 2.28.
<a href="https://www.benzinga.com/quote/ZYXI/earnings">To track all earnings releases for Zynex visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Preview: Zynex's Earnings

RBC Capital analyst Shagun Singh maintains Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) with a Outperform and lowers the price target from $12 to $11.

RBC Capital Maintains Outperform on Zynex, Lowers Price Target to $11

HC Wainwright &amp; Co. analyst Yi Chen reiterates Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) with a Buy and maintains $16 price target.

HC Wainwright & Co. Reiterates Buy on Zynex, Maintains $16 Price Target

Zynex Obtains FDA Xlearance For TensWave Device

Anna Lucsok, Chief Operating Officer at Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>), reported an insider sell on August 8, according to a new SEC filing. 
What Happened: Lucsok's decision to sell 24,875 shares of Zynex was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000846475/000141588924021011//Archives/edgar/data/846475/000141588924021011/0001415889-24-021011-index.htm">U.S. Securities and Exchange Commission</a> on Thursday. The total value of the sale is $199,410.
The latest market snapshot at Friday morning reveals Zynex shares down by 0.0%, trading at $7.84.
<h3>Discovering Zynex: A Closer Look</h3>
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.
<h3>Understanding the Numbers: Zynex's Finances</h3>
Revenue Growth: Over the 3 months period, Zynex showcased positive performance, achieving a revenue growth rate of 10.97% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 80.01%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Zynex's EPS is below the industry average. The company faced challenges with a current EPS of 0.04. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: Zynex's debt-to-equity ratio surpasses industry norms, standing at 2.28. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Financial Valuation Breakdown:
<ul>
<li>
Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 43.56 suggests caution, as the stock may be overvalued in the eyes of investors.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 1.37 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio of 19.67, the company's market valuation exceeds industry averages.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Cracking Transaction Codes</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000846475">Check Out The Full List Of Zynex's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Chief Operating Officer Of Zynex Sold $199K In Stock

Daniel Moorhead, Chief Financial Officer at Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>), reported an insider sell on July 30, according to a new SEC filing. 
What Happened: Moorhead's recent move involves selling 15,000 shares of Zynex. This information is documented in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000846475/000141588924020373//Archives/edgar/data/846475/000141588924020373/0001415889-24-020373-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The total value is $123,600.
During Wednesday's morning session, Zynex shares up by 5.84%, currently priced at $8.7.
<h3>Unveiling the Story Behind Zynex</h3>
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.
<h3>Zynex's Economic Impact: An Analysis</h3>
Revenue Growth: Zynex displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 10.97%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: With a high gross margin of 80.01%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): Zynex's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.04.
</li>
</ul>
Debt Management: Zynex's debt-to-equity ratio stands notably higher than the industry average, reaching 2.28. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: Zynex's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 45.67.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 1.43, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio of 20.48, the company's market valuation exceeds industry averages.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000846475">Check Out The Full List Of Zynex's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Sell Alert: Daniel Moorhead Cashes Out $123K In Zynex Stock

WIIM

Zynex shares are trading lower after the company reported worse-than-expected Q2 financial results and lowered its Q3 guidance below estimates. Additionally, multiple firms lowered their respective price targets on the stock.

Shares of Saia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) fell sharply during Friday's session after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/SAIA/earnings">second-quarter financial results</a>.
Saia reported quarterly earnings of $3.83 per share which missed the analyst consensus estimate of $4.00 per share. The company reported quarterly sales of $823.24 million which missed the analyst consensus estimate of $826.55 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Saia shares dipped 18.6% to $398.01 on Friday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>BurgerFi International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFI#NASDAQ">BFI</a>) gained 117.4% to $0.4639 after the company announced it reached a legal settlement agreement with Lion Point Capital. The company agreed to pay $1,350,000 and issue Lion Point 300,000 of preferred stock.</li>
<li>Windtree Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares jumped 101.3% to $6.67 after the company filed a request for the withdrawal of its registration statement on a Form S-1.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) gained 53% to $13.94.</li>
<li>Coursera, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) shares gained 46.2% to $10.83 after the company beat second-quarter earnings estimates.</li>
<li>Carbon Revolution Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREV#NASDAQ">CREV</a>) shares climbed 43.3% to $8.84. Carbon Revolution said it will supply the carbon fiber wheels available on the just-revealed Chevrolet Corvette ZR1.</li>
<li>Everi Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVRI#NYSE">EVRI</a>) rose 41.1% to $12.93 after it entered an agreement to be acquired by funds managed by Apollo affiliates for $14.25 per share in cash.</li>
<li>Nauticus Robotics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) gained 37% to $4.45.</li>
<li>Newell Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) jumped 36.6% to $8.66 on better-than-expected second-quarter earnings and raising FY24 outlook.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) gained 35% to $0.9043.</li>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) rose 28% to $1.55 after the company announced results from a bias analysis conducted for its concluded Phase 3 study of Multikine. Multikine cut the 5-year risk of death by half compared to control in its target population.</li>
<li>AudioEye, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) rose 25% to $24.52 following second-quarter results.</li>
<li>Pineapple Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAPL#NYSE">PAPL</a>) gained 24.4% to $1.1760. Pineapple Financial CSO Christa Lillian Mitchell bought a total of 2,000 shares at an average price of $0.88.</li>
<li>Douglas Elliman Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOUG#NYSE">DOUG</a>) climbed 23% to $1.66.</li>
<li>CareMax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) rose 19% to $6.71.</li>
<li>Liberty Broadband Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBRDA#NASDAQ">LBRDA</a>) rose 17.6% to $65.16.</li>
<li>Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) jumped 17% to $368.65 after the company reported better-than-expected second-quarter financial results.</li>
<li>Mohawk Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>) gained 16.5% to $156.70 following mixed second-quarter earnings.</li>
<li>Karooooo Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KARO#NASDAQ">KARO</a>) gained 16% to $33.40. Karooooo announced termination of secondary public offering of ordinary shares due to market conditions.</li>
<li>3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) climbed 15% to $118.99 after better-than-expected second-quarter financial results and FY24 EPS outlook raise.</li>
<li>International Game Technology PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGT#NYSE">IGT</a>) gained 13.4% to $22.86 after the company entered an agreement for its Gaming &amp; Digital business to be acquired by funds managed by affiliates of Apollo.</li>
<li>Altice USA, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATUS#NYSE">ATUS</a>) rose 12.1% to $1.76.</li>
<li>Stardust Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) rose 11% to $15.06.</li>
<li>Avantor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) surged 11% to $25.32 after the company reported better-than-expected second-quarter earnings results.</li>
<li>Norfolk Southern Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) gained 10.7% to $246.86 after the company reported better-than-expected second-quarter earnings results.</li>
<li>Selina Hospitality PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNA#NASDAQ">SLNA</a>) shares gained 10.4% to $0.0415 after falling over 17% on Thursday.</li>
<li>Viasat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>) rose 9% to $20.58. Viasat announced new reporting segment structure.</li>
<li>Deckers Outdoor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) shares gained 8.7% to $914.71 as the company reported better-than-expected results for the first quarter. The company said it still expects net sales to increase approximately 10% year-over-year in fiscal year 2025 to $4.7 billion.</li>
<li>Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) climbed 7.6% to $48.69 following strong second-quarter earnings and increased 2024 guidance.</li>
<li>Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) climbed 7.6% to $72.55 following better-than-expected second-quarter financial results and increased 2024 guidance.</li>
<li>Columbia Banking System, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>) rose 7.4% to $25.98 after the company reported better-than-expected quarterly earnings results. Also, multiple firms raised their respective price targets on its stock.</li>
<li>Aon plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) gained 6.8% to $319.30 after the company reported better-than-expected quarterly revenue results.</li>
<li>Ultra Clean Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) shares gained 4.7% to $47.26 following better-than-expected quarterly results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>NovaBay Pharmaceuticals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBY#NYSE">NBY</a>) shares dipped 59.6% to $0.7830 after the company reported pricing of $3.5 million underwritten public offering.</li>
<li>Tantech Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TANH#NASDAQ">TANH</a>) fell 46.9% to $0.2603.</li>
<li>Nature&#8217;s Miracle Holding Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) fell 46.4% to $0.2099 after the company announced pricing of $1.2 million public offering.</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) shares declined 40.7% to $63.97 after the company reported worse-than-expected second-quarter revenue results and issued weak FY24 revenue guidance.</li>
<li>Predictive Oncology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) fell 29.6% to $1.3150. Predictive Oncology announced exercise of warrants for $1.26 million gross proceeds.</li>
<li>ProMIS Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMN#NASDAQ">PMN</a>) declined 29.2% to $1.5006 as the company reported top-line data from its Phase 1a Alzheimer&#8217;s trial and announced up to $122.7 million private placement financing.</li>
<li>PS International Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) dipped 26.1% to $1.53</li>
<li>Grom Social Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GROM#NASDAQ">GROM</a>) fell 23.8% to $0.2751.</li>
<li>Ocean Power Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#NASDAQ">OPTT</a>) shares declined 23.2% to $0.3188 after reporting fourth-quarter results.</li>
<li>Avinger, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) fell 20.2% to $1.30.</li>
<li>Next Technology Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) declined 20.1% to $1.6299.</li>
<li>Zynex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) shares fell 18.9% to $8.27 after the company reported worse-than-expected second-quarter financial results.</li>
<li>2U, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>) declined 17.6% to $1.24.</li>
<li>Ur-Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URG#NYSE">URG</a>) shares dipped 13.4% to $1.1250 after the company announced a proposed public offering of common shares.</li>
<li>BJ&#8217;s Restaurants, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJRI#NASDAQ">BJRI</a>) fell 12.6% to $32.53 following quarterly results.</li>
<li>Booz Allen Hamilton Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) declined 11.8% to $135.36 following a first-quarter earnings miss and soft EPS guidance.</li>
<li>Advent Technologies Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADN#NASDAQ">ADN</a>) shares fell 11.2% to $4.40 after gaining 3% on Thursday.</li>
<li>Tarsus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARS#NASDAQ">TARS</a>) fell 9.1% to $25.67.</li>
<li>World Acceptance Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRLD#NASDAQ">WRLD</a>) dipped 7.8% to $134.62 following weak quarterly sales.</li>
<li>Forward Air Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>) fell 7.4% to $25.61.</li>
<li>Olin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) shares declined 7.2% to $44.56 following a second-quarter earnings miss.</li>
<li>Carter&#8217;s, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRI#NYSE">CRI</a>) shares fell 6.6% to $55.87 following weak quarterly sales.</li>
<li>Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) declined 6.3% to $213.01 after the European Medicines Agency adopted a negative opinion on the Marketing Authorization Approval for lecanemab.</li>
<li>Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) shares fell 6% to $38.18. Tandem Diabetes Care will release its second quarter results after the closing bell on Thursday, Aug. 1.</li>
<li>L3Harris Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) declined 4.6% to $232.05 following second-quarter results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39984491/nvidia-lockheed-martin-and-2-other-stocks-insiders-are-selling">Nvidia, Lockheed Martin And 2 Other Stocks Insiders Are Selling</a></li>
</ul>

Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session

RBC Capital analyst Shagun Singh maintains Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) with a Outperform and lowers the price target from $15 to $12.

RBC Capital Maintains Outperform on Zynex, Lowers Price Target to $12

U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Friday.
Shares of DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) fell sharply during Friday's pre-market trading after the company reported worse-than-expected second-quarter revenue results and issued <a href="https://www.benzinga.com/news/earnings/24/07/39971462/dexcom-stock-drops-after-mixed-q2-results-weak-forward-guidance">weak FY24 revenue guidance</a>.
DexCom reported quarterly earnings of 43 cents per share, which beat the analyst consensus estimate of 39 cents. Quarterly sales came in at $1.004 billion which missed the analyst consensus estimate of $1.036 billion.
DexCom sees third-quarter revenue in a range of $975 million to $1 billion, versus the $1.15 billion estimate, and full-year revenue in a range of $4. billion to $4.05 billion, versus the $4.33 billion estimate.
DexCom shares dipped 37% to $68.00 in the pre-market trading session.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Zynex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) shares declined 21.5% to $8.00 in pre-market trading after the company reported worse-than-expected second-quarter financial results.</li>
<li>Ur-Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URG#NYSE">URG</a>) shares fell 9.2% to $1.18 in pre-market trading after the company announced a proposed public offering of common shares.</li>
<li>Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) shares declined 9% to $36.99 in pre-market trading. Tandem Diabetes Care will release its second quarter results after the closing bell on Thursday, Aug. 1.</li>
<li>MacroGenics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) shares dipped 8.9% to $5.01 in pre-market trading after gaining 5% on Thursday.</li>
<li>Olin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) shares declined 8.1% to $44.15 in pre-market trading following a second-quarter earnings miss.</li>
<li>Carter&#8217;s, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRI#NYSE">CRI</a>) shares fell 7.4% to $55.40 in pre-market trading following weak quarterly sales.</li>
<li>Indivior PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDV#NASDAQ">INDV</a>) shares fell 4.4% to $12.52 in pre-market trading. Indivior shares jumped 20% on Thursday after the company reported better-than-expected second-quarter financial results and announced an accelerated $100 million share repurchase program.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39978094/s-p-500-nasdaq-settle-lower-as-tech-stocks-continue-to-falter-greed-index-in-fear-zone">S&amp;P 500, Nasdaq Settle Lower As Tech Stocks Continue To Falter: Greed Index In &#8216;Fear&#8217; Zone</a></li>
</ul>

DexCom, Zynex, Olin And Other Big Stocks Moving Lower In Friday's Pre-Market Session

HC Wainwright &amp; Co. analyst Yi Chen maintains Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) with a Buy and lowers the price target from $21 to $16.

HC Wainwright & Co. Maintains Buy on Zynex, Lowers Price Target to $16

Shares of Ultra Clean Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) shares surged 17.4% to $53.00 in pre-market trading following better-than-expected <a href="https://www.benzinga.com/quote/UCTT/earnings">quarterly results</a>.
Ultra Clean reported quarterly earnings of 32 cents per share which beat the analyst consensus estimate of 26 cents per share. The company reported quarterly sales of $516.100 million which beat the analyst consensus estimate of $490.064 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Ultra Clean shares jumped 17.4% to $53.00 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Windtree Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) rose 110.3% to $6.94 in pre-market trading. Windtree Therapeutics filed Form RW to withdraw registration statement on Form S-1.</li>
<li>BurgerFi International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFI#NASDAQ">BFI</a>) gained 83% to $0.39 in pre-market trading after the company announced it reached a legal settlement agreement with Lion Point Capital. The company agreed to pay $1,350,000 and issue Lion Point 300,000 of preferred stock.</li>
<li>Carbon Revolution Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREV#NASDAQ">CREV</a>) shares climbed 30.6% to $8.06 in pre-market trading. Carbon Revolution said it will supply the carbon fiber wheels available on the just-revealed Chevrolet Corvette ZR1.</li>
<li>Coursera, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) shares gained 24.7% to $9.24 in pre-market trading after the company beat second-quarter earnings estimates.</li>
<li>Zapata Computing Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZPTA#NASDAQ">ZPTA</a>) gained 24.5% to $0.6720 in pre-market trading.</li>
<li>Selina Hospitality PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNA#NASDAQ">SLNA</a>) shares gained 23.7% to $0.0465 in pre-market trading after falling over 17% on Thursday.</li>
<li>Mohawk Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>) gained 11.5% to $150.00 in pre-market trading following mixed second-quarter earnings.</li>
<li>Deckers Outdoor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) shares gained 11.2% to $935.45 in pre-market trading as the company reported better-than-expected results for the first quarter. The company said it still expects net sales to increase approximately 10% year-over-year in fiscal year 2025 to $4.7 billion.</li>
<li>Karooooo Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KARO#NASDAQ">KARO</a>) gained 9.4% to $31.50 in pre-market trading. Karooooo announced termination of secondary public offering of ordinary shares due to market conditions.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>NovaBay Pharmaceuticals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBY#NYSE">NBY</a>) shares fell 40.7% to $1.15 in pre-market trading after dipping 10% on Thursday.</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) shares declined 37% to $68.00 in pre-market trading after the company reported worse-than-expected second-quarter revenue results and issued weak FY24 revenue guidance.</li>
<li>Advent Technologies Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADN#NASDAQ">ADN</a>) shares fell 35.2% to $3.21 in pre-market trading after gaining 3% on Thursday.</li>
<li>Nature&#8217;s Miracle Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) shares fell 31.2% to $0.2696 in pre-market trading after declining around 9% on Thursday.</li>
<li>Ocean Power Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#NASDAQ">OPTT</a>) shares declined 21.7% to $0.3250 in pre-market trading after reporting fourth-quarter results.</li>
<li>Zynex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) shares fell 21.5% to $8.00 in pre-market trading after the company reported worse-than-expected second-quarter financial results.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) fell 16.4% to $0.4181 in pre-market trading after gaining around 25% on Thursday.</li>
<li>Conn&#8217;s, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CONN#NASDAQ">CONN</a>) fell 13.7% to $0.3528 in pre-market trading after surging 17% on Thursday.</li>
<li>Ur-Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URG#NYSE">URG</a>) shares dipped 9.2% to $1.18 in pre-market trading after the company announced a proposed public offering of common shares.</li>
<li>Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) shares fell 9% to $36.99 in pre-market trading. Tandem Diabetes Care will release its second quarter results after the closing bell on Thursday, Aug. 1.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39978094/s-p-500-nasdaq-settle-lower-as-tech-stocks-continue-to-falter-greed-index-in-fear-zone">S&amp;P 500, Nasdaq Settle Lower As Tech Stocks Continue To Falter: Greed Index In &#8216;Fear&#8217; Zone</a></li>
</ul>

Zynex Expects 2024 Net Revenue Of At Least $200M (Est $226.95M), EPS To Be At Least $0.20 (Est $0.51)

Here are the major earnings after the close today

Zynex GAAP EPS of $0.07 beats by $0.01, revenue of $49.97M misses by $0.86M

Zynex, Inc. (ZYXI) Q3 2024 Earnings Call Transcript

In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Zynex (ZYXI – Research Report), with a price target...

RBC Capital Keeps Their Buy Rating on Zynex (ZYXI)

Zynex (ZYXI) has completed its clinical verification trial for their NiCO pulse oximeter overseen by anesthesiologist Dr. David MacLeod at Duke Uni...

Zynex completes laser pulse oximetry trial

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zynex (ZYXI – Research Report) and KalVista Pharmace...

Analysts Are Bullish on These Healthcare Stocks: Zynex (ZYXI), KalVista Pharmaceuticals (KALV)

Zynex (ZYXI) announced highlights from a recent study comparing its NiCO laser pulse oximeter to conventional LED pulse oximeters for the effects o...

Zynex's NiCO oximeter avoids racial bias of standard laser pulse oximeters

Zynex (ZYXI) announced a new partnership to conduct business with Veterans Affairs Medical Centers – VAMCs – across the U.S. It is estimated that t...

Zynex partnering with Veterans Affairs Medical Centers

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Zynex (ZYXI – Research Report) on December 17 and set a price target of $11.00. ...

Zynex (ZYXI) Gets a Buy from RBC Capital

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Zynex (ZYXI – Research Report) on January 6 and set a price target of $11.00. Th...

RBC Capital Sticks to Its Buy Rating for Zynex (ZYXI)

APPF

BYON

CINF

ENSG

GLPI

KALV

KNSL

MGRC

SPSC

SSNC

TROX

TXRH

VALE

VRSN

Zynex Inc. CEO Thomas Sandgaard Discusses Significant Company Growth and Future Innovations

Press Releases

Zynex Obtains FDA clearance for new Pain Management Device

Zynex to Present at the HC Wainwright Global Investment Conference

Zynex Sets Third Quarter 2024 Earnings Call

Zynex Reports Third Quarter 2024 Financial Results

Building Momentum: Zynex Inc.'s (NASDAQ: ZYXI) Steady Rise in the Pain Management Market

Zynex Announces Open Oximetry Project Membership

Zynex Announces Completion of Its Laser Pulse Oximetry Trial

Zynex UCSF Study Results Demonstrate Laser Technology Benefits in Resolving Racial Bias of Current LED Pulse Oximeters

Zynex Announces Partnership To Conduct Business with Veterans Affairs (VA) Medical Centers, the Largest Healthcare Network in the United States

Comments

Zynex

Zynex (ZYXI) Forecast

Zynex (NASDAQ:ZYXI) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga